Public-Private Partnerships in TB Control: How Clinics and Pharmacies Join the Fight

Why governments and health organizations partner with private doctors and drugstores to find, treat, and cure tuberculosis faster.

By Garret Merkley · Explainer · Jun 13, 2026

Branched from Global Funding Initiatives for Tuberculosis Eradication Programs

Quick take

PPPs bring private clinics and pharmacies into TB control by setting shared standards, funding, and oversight so they diagnose and treat TB like public health programs do.
Private providers reach patients who skip public clinics, catch TB earlier, and reduce drug resistance through coordinated care.
Success depends on regulation, incentives, and real-time data sharing between private and public sectors.

A public-private partnership (PPP) in TB control is a formal agreement where government health agencies, NGOs, and international bodies work with private doctors, clinics, and pharmacies to diagnose, treat, and monitor tuberculosis patients using standardized protocols. Instead of TB care happening only in public hospitals—where many patients never go—PPPs extend evidence-based treatment into the private sector, which in many countries serves 30–70% of all patients seeking care. The goal is simple: catch TB earlier, treat it consistently, and stop drug-resistant strains from spreading.

How Private Providers Fit Into TB Control

In most low- and middle-income countries, patients visit private clinics and pharmacies first—not public TB programs. A person with a persistent cough is more likely to see a local doctor or buy antibiotics from a neighborhood pharmacy than to walk into a government TB center. PPPs recognize this reality and bring those private providers into the system. The partnership typically includes training private doctors on TB diagnosis and treatment guidelines, supplying them with quality-assured drugs, and creating a pathway for them to report cases to the public TB program so patients don't fall through the cracks.

The Mechanics: Training, Supply, and Accountability

PPPs operate through three overlapping mechanisms. First, the public sector trains private clinicians on TB diagnosis (using rapid tests like GeneXpert MTB/RIF) and standardized treatment regimens, often with refresher courses and certification. Second, partnerships ensure private clinics and pharmacies have access to quality TB drugs at affordable or subsidized prices, preventing substandard medicines that fuel drug resistance. Third, and most important, PPPs establish reporting systems: when a private doctor diagnoses TB, they notify the public TB program, which then monitors the patient's treatment adherence and outcomes. Some models also include financial incentives—paying private providers per case diagnosed or treated successfully—to motivate participation.

Data sharing is the backbone of accountability. A patient treated at a private clinic must be tracked in the same national TB register as one treated publicly, allowing the program to know if treatment was completed, if the patient was cured, or if they defaulted. Without this link, TB cases disappear from official statistics and drug-resistant TB can spread undetected. Modern PPPs use digital platforms—mobile apps, SMS alerts, or web portals—to make reporting seamless and real-time.

Why PPPs Matter for TB Control

TB is a disease of delay. The longer a patient waits to start treatment, the more people they infect and the higher the risk they develop drug-resistant TB. By bringing diagnosis and treatment into private clinics—where many patients already go—PPPs shrink that delay. Studies in India, the Philippines, and Nigeria show that PPPs increase TB case notifications by 15–40% because cases that were previously invisible in the private sector are now counted and treated. PPPs also reduce the burden on overcrowded public TB clinics, freeing resources for the hardest-to-reach patients. For patients, PPPs offer convenience: they can receive TB care closer to home and work, in a setting they trust, without the stigma sometimes attached to public TB programs.

From a drug-resistance perspective, PPPs are critical. Unregulated private clinics often prescribe incomplete TB regimens, wrong drug combinations, or substandard medicines—all drivers of multidrug-resistant TB (MDR-TB). When PPPs enforce standardized treatment and quality drug supply, they cut the risk of resistance. This protects not just individual patients but entire communities.

Real-World Models and Implementation

PPPs take different forms depending on the country and context. In India, the Revised National TB Control Programme partners with thousands of private practitioners through accreditation schemes: doctors are trained, audited, and supplied with TB drugs in exchange for reporting all cases to the program. In the Philippines, PPPs include drug-resistant TB centers run by private hospitals alongside public facilities. In Africa, some partnerships focus on pharmacy networks, training pharmacists to recognize TB symptoms and refer patients for testing while ensuring they don't dispense TB drugs without a diagnosis. The most successful models combine light-touch regulation (not heavy-handed control) with genuine incentives, whether financial, reputational, or operational.

Common PPP Components

Standardized TB diagnosis protocols and rapid testing availability
Centralized, quality-assured drug supply at subsidized or no cost
Training and certification of private clinicians
Mandatory case notification to the public TB program
Real-time digital tracking of patient treatment and outcomes
Financial or non-financial incentives for private providers
Regular audits and performance reviews

Challenges and Barriers

PPPs sound logical but face real obstacles. Private providers may see TB patients as low-profit cases and resist standardized treatment that cuts their earnings. Trust is fragile: public health officials may distrust private doctors' competence, while private clinicians may resent government oversight. Data sharing requires infrastructure and ongoing communication that many countries lack. In some settings, informal pharmacies—unlicensed, unregulated shops—dominate the market and cannot be easily brought into a PPP. Cultural and economic factors also play a role: patients may prefer private care but cannot afford it, or they may distrust both public and private providers. Sustaining PPPs requires long-term funding and political will; short-term projects often collapse once external funding ends.

When and Where PPPs Work Best

PPPs are most effective in countries with a significant private health sector (India, Philippines, Indonesia, parts of Africa) and enough institutional capacity to manage coordination and data systems. They work best when TB burden is high enough to justify investment and when there is political commitment from both public and private leaders. PPPs are less relevant in countries with strong public health systems where most patients already use government services, though they can still fill gaps. They also require a baseline level of private provider density—a rural area with one doctor per 50,000 people cannot sustain a meaningful PPP.

Do PPPs mean private clinics replace public TB programs?

No. PPPs complement public programs; they don't replace them. Public TB centers remain the backbone, providing care to the poorest and most vulnerable patients who cannot pay. PPPs extend capacity and reach, especially among patients who use private care first. The two sectors should work together, not compete.

How do you prevent private doctors from over-treating or under-treating TB?

Through standardized protocols, training, and audits. PPPs provide private clinicians with clear, evidence-based guidelines for TB diagnosis and treatment. Regular audits check whether they are following these guidelines. Digital tracking systems flag anomalies—a doctor treating TB for 3 months instead of 6, for example. Peer review and loss of partnership status are consequences for non-compliance.

What happens if a private clinic doesn't report a TB case?

That's a major gap. PPPs try to prevent this by making reporting mandatory, easy (digital systems), and incentivized (payment per case). But enforcement is weak in many countries. Some PPPs use spot checks or patient interviews to catch unreported cases. The most effective approach is making reporting so routine and low-burden that it becomes habitual, rather than relying on punishment.

Are private TB drugs as good as public ones?

They can be, but not always. Unregulated private pharmacies may stock substandard or counterfeit drugs. PPPs address this by supplying private clinics and pharmacies with quality-assured TB drugs from approved manufacturers, often at cost or below cost. This ensures patients get the same effective drugs whether they are treated privately or publicly.

How much do PPPs cost compared to public-only TB programs?

PPPs can be cost-effective if they increase case detection and treatment success without requiring massive new infrastructure. The main costs are training, drug supply, data systems, and coordination staff. In high-burden countries, the return on investment is often strong because early detection and consistent treatment prevent more expensive complications and drug resistance. However, PPPs do require upfront investment and ongoing funding.

Sources

World Health Organization. Public-Private Mix for TB Control in Asia-Pacific Region. WHO Regional Office for South-East Asia.
Lönnroth, K., et al. (2015). Drivers of tuberculosis epidemics: the role of risk, demographics and social determinants. The Lancet Infectious Diseases, 15(10), 1195–1202.
Chakaya, J., et al. (2021). Tuberculosis infection prevention and control in sub-Saharan Africa. The Lancet Respiratory Medicine, 9(4), 412–425.